111 related articles for article (PubMed ID: 12020160)
1. Summaries for patients. Alendronate improves osteoporosis in elderly women living in long-term care facilities.
Ann Intern Med; 2002 May; 136(10):I54. PubMed ID: 12020160
[No Abstract] [Full Text] [Related]
2. Alendronate improves bone mineral density in elderly women with osteoporosis residing in long-term care facilities. A randomized, double-blind, placebo-controlled trial.
Greenspan SL; Schneider DL; McClung MR; Miller PD; Schnitzer TJ; Bonin R; Smith ME; DeLucca P; Gormley GJ; Melton ME
Ann Intern Med; 2002 May; 136(10):742-6. PubMed ID: 12020142
[TBL] [Abstract][Full Text] [Related]
3. Ten years of alendronate treatment for osteoporosis in postmenopausal women.
Chan AS
N Engl J Med; 2004 Jul; 351(2):190-2; author reply 190-2. PubMed ID: 15250065
[No Abstract] [Full Text] [Related]
4. Osteoporosis and thyrotropin-suppressive therapy: reduced effectiveness of alendronate.
Panico A; Lupoli GA; Fonderico F; Marciello F; Martinelli A; Assante R; Lupoli G
Thyroid; 2009 May; 19(5):437-42. PubMed ID: 19415993
[TBL] [Abstract][Full Text] [Related]
5. Vitamin D status and bone mineral density changes during alendronate treatment in postmenopausal osteoporosis.
Roux C; Binkley N; Boonen S; Kiel DP; Ralston SH; Reginster JY; Pong A; Rosenberg E; Santora A;
Calcif Tissue Int; 2014 Feb; 94(2):153-7. PubMed ID: 23912950
[TBL] [Abstract][Full Text] [Related]
6. The patient's page. Bone health facts.
McKinney J
South Med J; 2005 Oct; 98(10):1058. PubMed ID: 16295830
[No Abstract] [Full Text] [Related]
7. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis.
Black DM; Greenspan SL; Ensrud KE; Palermo L; McGowan JA; Lang TF; Garnero P; Bouxsein ML; Bilezikian JP; Rosen CJ;
N Engl J Med; 2003 Sep; 349(13):1207-15. PubMed ID: 14500804
[TBL] [Abstract][Full Text] [Related]
8. Minimum required vitamin D level for optimal increase in bone mineral density with alendronate treatment in osteoporotic women.
Ishijima M; Sakamoto Y; Yamanaka M; Tokita A; Kitahara K; Kaneko H; Kurosawa H
Calcif Tissue Int; 2009 Nov; 85(5):398-404. PubMed ID: 19795092
[TBL] [Abstract][Full Text] [Related]
9. Superiority of a combined treatment of Alendronate and Alfacalcidol compared to the combination of Alendronate and plain vitamin D or Alfacalcidol alone in established postmenopausal or male osteoporosis (AAC-Trial).
Ringe JD; Farahmand P; Schacht E; Rozehnal A
Rheumatol Int; 2007 Mar; 27(5):425-34. PubMed ID: 17216477
[TBL] [Abstract][Full Text] [Related]
10. Strontium: new drug. Postmenopausal osteoporosis: too many unknowns.
Prescrire Int; 2005 Dec; 14(80):207-11. PubMed ID: 16397977
[TBL] [Abstract][Full Text] [Related]
11. Calcium, vitamin D and vitamin K in the prevention of fractures due to osteoporosis.
Meunier PJ
Osteoporos Int; 1999; 9 Suppl 2():S48-52. PubMed ID: 10525726
[No Abstract] [Full Text] [Related]
12. Treatment with alendronate plus calcium, alendronate alone, or calcium alone for postmenopausal low bone mineral density.
Bonnick S; Broy S; Kaiser F; Teutsch C; Rosenberg E; DeLucca P; Melton M
Curr Med Res Opin; 2007 Jun; 23(6):1341-9. PubMed ID: 17594775
[TBL] [Abstract][Full Text] [Related]
13. Postmenopausal osteoporosis.
Diab DL; Watts NB
Curr Opin Endocrinol Diabetes Obes; 2013 Dec; 20(6):501-9. PubMed ID: 24150190
[TBL] [Abstract][Full Text] [Related]
14. Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial.
Greenspan SL; Emkey RD; Bone HG; Weiss SR; Bell NH; Downs RW; McKeever C; Miller SS; Davidson M; Bolognese MA; Mulloy AL; Heyden N; Wu M; Kaur A; Lombardi A
Ann Intern Med; 2002 Dec; 137(11):875-83. PubMed ID: 12458987
[TBL] [Abstract][Full Text] [Related]
15. Effects of odanacatib on BMD and safety in the treatment of osteoporosis in postmenopausal women previously treated with alendronate: a randomized placebo-controlled trial.
Bonnick S; De Villiers T; Odio A; Palacios S; Chapurlat R; DaSilva C; Scott BB; Le Bailly De Tilleghem C; Leung AT; Gurner D
J Clin Endocrinol Metab; 2013 Dec; 98(12):4727-35. PubMed ID: 24064689
[TBL] [Abstract][Full Text] [Related]
16. Does alendronate treatment prevent vertebral fractures in men with osteoporosis?
Li I
J Fam Pract; 2000 Dec; 49(12):1077. PubMed ID: 11132054
[No Abstract] [Full Text] [Related]
17. Is there a role for a random measurement of 24-hour urine calcium excretion in the determination of calcium supplementation in osteoporotic postmenopausal women using alendronate?
Pines A; Weisman Y; Ayalon D; Shapira I
Gynecol Endocrinol; 2005 Jan; 20(1):45-7. PubMed ID: 15969246
[TBL] [Abstract][Full Text] [Related]
18. Changes in blood and urinary cadmium levels and bone mineral density according to osteoporosis medication in individuals with an increased cadmium body burden.
Eom SY; Yim DH; Hong SM; Kim YD; Kim H; Choi BS; Park JD; Park CH; Kim GB; Yu SD
Hum Exp Toxicol; 2018 Apr; 37(4):350-357. PubMed ID: 28441892
[TBL] [Abstract][Full Text] [Related]
19. Osteoporosis: protecting bone mass with fundamentals and drug therapy.
Kleerekoper M
Geriatrics; 1999 Jul; 54(7):38-43; quiz 44. PubMed ID: 10431598
[No Abstract] [Full Text] [Related]
20. Effect of estrogen replacement plus low-dose alendronate treatment on bone density in surgically postmenopausal women with osteoporosis.
Palomba S; Orio F; Colao A; di Carlo C; Sena T; Lombardi G; Zullo F; Mastrantonio P
J Clin Endocrinol Metab; 2002 Apr; 87(4):1502-8. PubMed ID: 11932272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
